BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations

American Journal of Surgical Pathology

Volumn 39, Issue 7, 2015, Pages 977-982

  Sheffield, Brandon S ^a   Hwang, Harry C ^c   Lee, Anna F ^b   Thompson, Kim ^c   Rodriguez, Stephanie ^c   Tse, Christopher H ^c   Gown, Allen M ^c   Churg, Andrew ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^c PHENOPATH LABORATORIES   (United States)

Author keywords

9p21; BAP1; BRCA associated protein 1; CDKN2A; mesothelioma; p16

Indexed keywords

BAP1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; EPITHELIUM; EVALUATION STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MESOTHELIOMA; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DIAGNOSIS, DIFFERENTIAL; EPITHELIUM; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MESOTHELIOMA; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84933680033     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000394     Document Type: Article

References (30)

1. Husain AN, Colby T, Odonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137:647-667.
2. Henderson DW, Reid G, Kao SC, et al. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013;66:847-853.
3. Churg A, Galateau-Salle F. The separation of benign and malignant mesothelial proliferations. Arch Pathol Lab Med. 2012;136:1217-1226.
4. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215-220.
5. Shi M, Fraire AE, Chu P, et al. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011;35:878-882.
6. Cagle PT, Brown RW, Lebovitz RM. P53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. Hum Pathol. 1994;25:443-448.
7. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochem-istry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. Histopathology. 2003;43:231-238.
8. King J, Thatcher N, Pickering C, et al. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports. Histopathology. 2006;49:561-568.
9. Lee AF, Gown AM, Churg A. IMP3 and GLUT-1 immunohis-tochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol. 2013;37:421-426.
10. Illei PB, Ladanyi M, Rusch VW, et al. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer. 2003;99:51-56.
11. Monaco SE, Shuai Y, Bansal M, et al. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135:619-627.
12. Ladanyi M. Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer. 2005;49(S1):S95-S98.
13. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022-1025.
14. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. 2013;45:116-126.
15. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43: 668-672.
16. Koopmans AE, Verdijk RM, Brouwer RW, et al. Clinical significance of immunohistochemistry for deletion of BAP1 mutations in uveal melanoma. Mod Pathol. 2014;27:1321-1330.
17. Joseph RW, Kapur P, Serie DJ, et al. Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma. Cancer. 2014;120: 1059-1067.
18. Cao C, Yan TD, Deraco M, et al. Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol. 2012;23:1494-1498.
19. Chung CT, Santos Gda C, Hwang DM, et al. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol. 2010;63:630-634.
20. Chiosea S, Krasinskas A, Cagle PT, et al. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008;21:742-747.
21. Hwang H, Tse C, Rodriguez S, et al. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma. Am J Surg Pathol. 2014;38:681-688.
22. Wu D, Hiroshima K, Matsumoto S, et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013;139: 39-46.
23. Tochigi N, Attanoos R, Chirieac LR, et al. p16 Deletion in sarcomatoid tumors of the lung and pleura. Arch Pathol Lab Med. 2013;137:632-636.
24. Betti M, Casalone E, Ferrante D, et al. Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes Chromosomes Cancer. 2015;54:51-62.
25. Kalirai H, Dodson A, Fagir S, et al. Lack of BAP1 protein expression in uveal melanoma is associated with increased meta-static risk and has utility in routine prognostic testing. Br J Cancer. 2014;111:1373-1380.
26. Shah AA, Bourne TD, Murali R. BAP1 protein loss by immuno-histochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma Pathology. 2013;45:651-656.
27. Zauderer MG, Bott M, McMillan R, et al. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations. J Thorac Oncol. 2013;8:1430-1433.
28. De la Fouchardiere A, Cabaret O, Savin L, et al. Germline BAP1 mutations predispose also to basal cell carcinomas. Clin Genet. 2014. [Epub ahead of print].
29. Ladanyi M, Zauderer MG, Krug LM, et al. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. 2012;18:4485-4490.
30. Battaglia A. The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: clinical management and risk assessment. Clin Med Insights Oncol. 2014;8: 37-47.